KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced today that it has been awarded by the National Institutes of Health a five year U01 cooperative agreement, to develop a novel biased ligand to the delta opioid receptor for major depressive disorder.
